Table 2 Clinical features of patients with CRLM( +) and CRLM(−) in the training and validation cohorts.
From: Prediction of colorectal cancer liver metastasis through an MRI radiomic model
Training | Validation | |||||
|---|---|---|---|---|---|---|
CRLM(+) (n = 76) | CRLM(-) (n = 83) | P value | CRLM(+) (n = 10) | CRLM(-) (n = 25) | P value | |
Age/yr (Mean ± SD) | 64.05 ± 11.80 | 58.98 ± 12.73 | 0.010 | 65.90 ± 10.58 | 61.60 ± 11.10 | 0.302 |
Sex (%) | 0.132 | 1.000 | ||||
Male | 57(75.0) | 52(62.7) | 7(70.0) | 17(68.0) | ||
Female | 19(25.0) | 31(37.3) | 3(30.0) | 8(32.0) | ||
MRT stage (%) | 0.988 | 0.302 | ||||
T1 | 0(0) | 1(1.2) | 0(0) | 1(4.0) | ||
T2 | 1(1.3) | 14(16.9) | 1(10.0) | 2(8.0) | ||
T3 | 48(63.2) | 46(55.4) | 3(30.0) | 15(60.0) | ||
T4 | 27(35.5) | 22(26.5) | 6(60.0) | 7(28.0) | ||
MRN stage (%) | 0.887 | 0.439 | ||||
N0 | 13(17.1) | 20(24.1) | 1(10.0) | 7(28.0) | ||
N1 | 22(28.9) | 22(26.5) | 3(30.0) | 8(32.0) | ||
N2 | 41(53.9) | 41(49.4) | 6(60.0) | 10(40.0) | ||
CEA level (ng/mL) | 310.77 ± 1315.32 | 4.99 ± 6.81 | < 0.001 | 108.10 ± 313.64 | 6.10 ± 13.28 | 0.050 |
CA19-9 level (U/mL) | 1549.28 ± 9407.46 | 17.32 ± 14.10 | < 0.001 | 19.64 ± 11.42 | 16.70 ± 25.59 | 0.083 |
